Kahan B D, Tanaka T, Pellis N R
J Natl Cancer Inst. 1980 Nov;65(5):1001-4.
Tumor-specific transplantation antigens (TSTA), extracted from the 3-methylcholanthrene-induced sarcoma MCA-F and partially purified by flat-bed isoelectric focusing, were used to treat syngeneic inbred C3H/HeJ mice bearing supralethal neoplastic challenges. Three weekly injections of 25 micrograms TSTA increased the survival times of hosts inoculated 1 day earlier with ten times the lethal dose of MCA-F cells. In another protocol TSTA injections decreased the incidence and outgrowth of a local metastasis in mice given sc supralethal inoculations and completely resected of established 1-cm tumors. In addition, weekly injections of 25 micrograms MCA-F TSTA decreased the tumor recurrence rate and increased the survival times of hosts with recurrent neoplastic disease by virtue of residual tumor cells following resection of 2-cm masses. The therapeutic effect of TSTA was immunologically specific: Animals cured of local MCA-F recurrences promptly died from primary challenge with the non-cross-reacting sarcoma MCA-D. The results suggest that active specific immunotherapy may represent a useful adjunct to treatment of hosts bearing modest tumor burdens.
从3-甲基胆蒽诱导的肉瘤MCA-F中提取并通过平板等电聚焦部分纯化的肿瘤特异性移植抗原（TSTA），被用于治疗受到超致死性肿瘤攻击的同基因近交C3H/HeJ小鼠。每周三次注射25微克TSTA可延长在1天前接种十倍致死剂量MCA-F细胞的宿主的存活时间。在另一个方案中，TSTA注射降低了接受皮下超致死接种并完全切除已形成的1厘米肿瘤的小鼠局部转移的发生率和生长。此外，每周注射25微克MCA-F TSTA可降低肿瘤复发率，并延长因切除2厘米肿块后残留肿瘤细胞而患有复发性肿瘤疾病的宿主的存活时间。TSTA的治疗效果具有免疫特异性：治愈局部MCA-F复发的动物在用非交叉反应性肉瘤MCA-D进行初次攻击后迅速死亡。结果表明，主动特异性免疫疗法可能是治疗肿瘤负荷适中的宿主的一种有用辅助手段。
